GlassScriptPhysician profile
Charles H Bonner
NPI 1710983283
$3,977.91
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,054 · 2020: $657 · 2021: $848 · 2022: $700 · 2023: $676 · 2024: $42.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $719.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $715.41 | 2021-2024 | Ubrelvy, Qulipta, Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $475.06 | 2019-2023 | Relistor |
| Arbor Pharmaceuticals, INC. | $446.04 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $389.75 | 2019-2024 | Xtampza |
| Horizon Therapeutics Plc | $289.73 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $164.77 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $148.68 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $108.19 | 2021 | |
| Biodelivery Sciences International, INC. | $94.30 | 2019-2021 | |
| Orexo US, INC. | $75.88 | 2019-2020 | |
| Bioventus LLC | $73.98 | 2020-2021 | |
| Redhill Biopharma INC. | $71.71 | 2020-2021 | |
| Pfizer INC. | $71.01 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $70.65 | 2022 | |
| Mdd US Operations, LLC | $60.89 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Bonner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.